6 резултати
FIELD OF THE INVENTION
The present invention relates generally to compositions and methods for the treatment of cardiovascular disease. More particularly, the present invention relates to modifying thrombus formation and growth by administering a heparin cofactor II-specific (HCII) catalytic agent
FIELD OF THE INVENTION
The present invention relates generally to compositions and methods for the treatment of cardiovascular disease. More particularly, the present invention relates to modifying thrombus formation and growth by administering an agent capable of selectively inactivating thrombin
FIELD OF THE INVENTION
The present invention relates generally to compositions and methods for the treatment of cardiovascular disease. More particularly, the present invention relates to modifying thrombus formation and growth by administering an agent which, inter alia, is capable of (1)
BACKGROUND OF THE INVENTION
It has been more than four decades since the introduction of heparin, warfarin and indandione derivatives for the treatment and preventing of thromboembolic disorders. These drugs remain to be the only effective anticoagulants in use today. They exert their effects by
FIELD OF THE INVENTION
The present invention relates generally to processes for the preparation of low affinity, low molecular weight heparins (LA-LMW-heparins) which are useful, inter alia, as antithrombotics. More particularly, the present invention relates to processes for the preparation of
FIELD OF THE INVENTION
The present invention relates generally to compositions and methods for the treatment of cardiovascular disease. More particularly, the present invention relates to modifying thrombus formation and growth by administering a modified low molecular weight heparin (MLMWH) that,